The Conversation (0)
BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet
Jun. 24, 2019 08:43AM PST
Medical Device Investing
BrainsWay (NASDAQ:BWAY, TASE:BWAY) has announced that it has shipped its 100th Deep Transcranial Magnetic Stimulation (Deep TMS) system to treat major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). As quoted in the press release: Yaacov Michlin, President and Chief Executive Officer of BrainsWay, said, “The shipment of our 100th OCD coil represents an important milestone for …
BrainsWay (NASDAQ:BWAY, TASE:BWAY) has announced that it has shipped its 100th Deep Transcranial Magnetic Stimulation (Deep TMS) system to treat major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
As quoted in the press release:
Yaacov Michlin, President and Chief Executive Officer of BrainsWay, said, “The shipment of our 100th OCD coil represents an important milestone for BrainsWay. Our Deep TMS technology is the only TMS product currently available for OCD patients, and the shipment of OCD helmets to 100 locations across the U.S. allows us to access a large and growing number of patients who are in desperate need of a non-invasive, safe and effective treatment option. Moreover, this key achievement is indicative of the substantial physician demand that exists for additional treatment options for patients with OCD.”
Dr. Ryan Vidrine, Director of OCD program at TMS Health Solutions, said, “OCD is a devastating and debilitating mental health disorder. Integrating the Deep TMS system into my practice has allowed me to further help many OCD patients find relief from the intrusive OCD symptoms they suffer from daily.”
Dr. Geoffrey Grammar, Chief Medical Officer of Greenbrook TMS, added, “By receiving and utilizing BrainsWay’s Deep TMS technology for OCD, we have been able to provide our patients with a novel approach to symptom relief, ensuring they receive the very best care possible.”
